At the time of writing, Cogent Biosciences Inc [COGT] stock is trading at $16.0, down -0.56%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The COGT shares have gain 7.74% over the last week, with a monthly amount glided 11.42%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cogent Biosciences Inc [NASDAQ: COGT] stock has seen the most recent analyst activity on October 16, 2025, when Stifel initiated its Hold rating and assigned the stock a price target of $16. Previously, Raymond James started tracking the stock with Strong Buy rating on September 03, 2025, and set its price target to $30. On March 07, 2025, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $17 on the stock. Needham downgraded its rating to a Hold. Robert W. Baird downgraded its rating to a Neutral and reduced its price target to $8 on February 26, 2024. Citigroup started tracking with a Buy rating for this stock on February 08, 2024, and assigned it a price target of $11. In a note dated December 11, 2023, Wedbush downgraded a Neutral rating on this stock but restated the target price of $5.
For the past year, the stock price of Cogent Biosciences Inc fluctuated between $3.72 and $17.15. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. Cogent Biosciences Inc [NASDAQ: COGT] shares were valued at $16.0 at the most recent close of the market. An investor can expect a potential return of 37.5% based on the average COGT price forecast.
Analyzing the COGT fundamentals
Gross Profit Margin for this corporation currently stands at -0.29% with Operating Profit Margin at -69.82%, Pretax Profit Margin comes in at -66.19%, and Net Profit Margin reading is -66.19%. To continue investigating profitability, this company’s Return on Assets is posted at -1.03, Equity is -1.2 and Total Capital is -1.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.75 points at the first support level, and at 15.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.33, and for the 2nd resistance point, it is at 16.67.
Ratios To Look Out For
It is important to note that Cogent Biosciences Inc [NASDAQ:COGT] has a current ratio of 4.19. Further, the Quick Ratio stands at 4.19, while the Cash Ratio is 2.18.
Transactions by insiders
Recent insider trading involved Fairmount Funds Management LLC, Director, that happened on Jul 10 ’25 when 2.78 million shares were purchased. Chief Commercial Officer, Pinnow Cole completed a deal on Jan 14 ’25 to buy 43750.0 shares.
